Apoptosis pathways and oncolytic adenoviral vectors: Promising targets and tools to overcome therapy resistance of malignant melanoma

Experimental Dermatology

Volumn 17, Issue 1, 2008, Pages 1-11

  Eberle, Jürgen ^a   Fecker, Lothar F ^a   Hossini, Amir M ^a   Kurbanov, Bahtier M ^a   Fechner, Henry ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Bcl 2 proteins; Death ligands; Melanoma; Oncolytic adenoviral vectors

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; APRIL PROTEIN; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; COMPLEMENTARY DNA; DACARBAZINE; FAS LIGAND; GAMMA INTERFERON; GLYCOPROTEIN E1; H 101; OBLIMERSEN; ONCOLYTIC ADENOVIRUS; ONYX 015; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN BIK; PROTEIN MDM2; PROTEIN P53; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND DERIVATIVE; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TW 37; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL DIVISION; CHILL; CLINICAL TRIAL; COLORECTAL CARCINOMA; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; FLU LIKE SYNDROME; GENE ACTIVATION; GENE IDENTIFICATION; GENE INACTIVATION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LIGAND BINDING; LUNG CANCER; MELANOMA; MELANOMA CELL; MONOTHERAPY; MYALGIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; GENETIC VECTORS; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 37249067981     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2007.00655.x     Document Type: Review

References (141)

1. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001: 14: 280-290.
2. Lens M B, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004: 150: 179-185.
3. Eigentler T K, Caroli U M, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised clinical trials. Lancet Oncol 2003: 4: 748-759.
4. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006: 17: 563-570.
5. Tuettenberg A, Schmitt E, Knop J, Jonuleit H. Dendritic cell-based immunotherapy of malignant melanoma: Success and limitations. J Dtsch Dermatol Ges 2007: 5: 190-196.
6. Becker J C, Kirkwood J M, Agarwala S S, Dummer R, Schrama D, Hauschild A. Molecularly targeted therapy for melanoma -current reality and future options. Cancer 2006: 107: 2317-2327.
7. Fensterle J. A trip through the signaling pathways of melanoma. J Dtsch Dermatol Ges 2006: 4: 205-217.
8. Lejeune F J, Rimoldi D, Speiser D. New approaches in metastatic melanoma: Biological and molecular targeted therapies. Expert Rev Anticancer Ther 2007: 7: 701-713.
9. Meier F, Schittek B, Busch S et al. The Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Frontiers Biosci 2005: 10: 2986-3001.
10. Kerr J F, Wyllie A H, Currie A R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972: 26: 239-257.
11. Russell J H, Ley T J. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002: 20: 323-370.
12. Peter M E, Krammer P H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003: 10: 26-35.
13. Engels I H, Totzke G, Fischer U, Schulze-Osthoff K, Janicke R U. Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner. Mol Cell Biol 2005: 25: 2808-2818.
14. Los M, Stroh C, Janicke R U, Engels I H, Schulze-Osthoff K. Caspases: more than just killers? Trends Immunol 2001: 22: 31-34.
15. Daniel P T, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001: 15: 1022-1032.
16. Harris S L, Levine A J. The p53 pathway: Positive and negative feedback loops. Oncogene 2005: 24: 2899-2908.
17. Roos W P, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006: 12: 440-450.
18. Er E, Oliver L, Cartron P F, Juin P, Manon S, Vallette F M. Mitochondria as the target of the pro-apoptotic protein Bax. Biochim Biophys Acta 2006: 1757: 1301-1311.
19. Shi Y. Mechanical aspects of apoptosome assembly. Curr Opin Cell Biol 2006: 18: 677-684.
20. Daniel P T, Schulze-Osthoff K, Belka C, Guner D. Guardians of cell death: The Bcl-2 family proteins. Essays Biochem 2003: 39: 73-88.
21. Sheikh M S, Fornace A J Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000: 14: 1509-1513.
22. Tomasetti M, Andera L, Alleva R, Borghi B, Neuzil J, Procopio A. Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: Implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Lett 2006: 580: 1925-1931.
23. Ward M W, Rehm M, Duessmann H, Kacmar S, Concannon C G, Prehn JH. Real time single cell analysis of Bid cleavage and Bid translocation during caspase-dependent and neuronal caspase-independent apoptosis. J Biol Chem 2006: 281: 5837-5844.
24. Lu H, Lu H F, Hou Q et al. Granzyme M directly cleaves inhibitor of caspase-activated DNase (CAD) to unleash CAD leading to DNA fragmentation. J Immunol 2006: 177: 1171-1178.
25. Fischer U, Janicke R U, Schulze-Osthoff K. Many cuts to ruin: A comprehensive update of caspase substrates. Cell Death Differ 2003: 10: 76-100.
26. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005: 52: 109-118.
27. Sjostrom J, Bergh J. How apoptosis is regulated, and what goes wrong in cancer. BMJ 2001: 322: 1538-1539.
28. Reed J C, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 2005: 106: 408-418.
29. Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ 2005: 12: 942-961.
30. Soengas M S, Lowe S W. Apoptosis and melanoma chemoresistance. Oncogene 2003: 22: 3138-3151.
31. Hofseth L J, Hussain S P, Harris C C. p53: 25years after its discovery. Trends Pharmacol Sci 2004: 25: 177-181.
32. Satyamoorthy K, Chehab N H, Waterman M J et al. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ 2000: 11: 467-474.
33. Kichina J V, Rauth S, Das Gupta T K, Gudkov A V. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53. Oncogene 2003: 22: 4911-4917.
34. Smalley K S M, Contractor R, Haass N K et al. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 2007: 67: 209-217.
35. Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol 2005: 125: 1242-1251.
36. Papp T, Niemetz A, Dosdahl N, Kumar K, Schiffmann D. Mutational analysis of Chk1, Chk2, Apaf1 and Rb1 in human malignant melanoma cell lines. Oncol Rep 2007: 17: 135-140.
37. Soengas M S, Capodieci P, Polsky D et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001: 409: 207-211.
38. Fujimoto A, Takeuchi H, Taback B et al. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 2004: 64: 2245-2250.
39. Baldi A, Santini D, Russo P et al. Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol 2004: 13: 93-97.
40. Campioni M, Santini D, Tonini G et al. Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol 2005: 14: 811-818.
41. Niedojadlo K, Labedzka K, Lada E, Milewska A, Chwirot B W. Apaf-1 expression in human cutaneous melanoma progression and in pigmented nevi. Pigment Cell Res 2006: 19: 43-50.
42. Zanon M, Piris A, Bersani I et al. Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 2004: 64: 7386-7394.
43. Rockmann H, Schadendorf D. Role of Apaf-1 in melanoma drug resistance and apoptosis. J Investi Dermatol 2005: 125: 386-387.
44. Grossman D, McNiff J M, Li F, Altieri D C. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999: 113: 1076-1081.
45. Takeuchi H, Morton D L, Elashoff D, Hoon D S. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 2005: 117: 1032-1038.
46. Chawla-Sarkar M, Bae S I, Reu F J, Jacobs B S, Lindner D J, Borden E C. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004: 11: 915-923.
47. Yan H, Thomas J, Liu T et al. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist. Oncogene 2006: 25: 6968-6974.
48. Kluger H M, McCarthy M M, Alvero A B et al. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by phenoxodiol is associated with carboplatin sensitization. J Transl Med 2007: 5: 6.
49. Kasof G M, Gomes B C. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001: 276: 3238-3246.
50. Yan H, Brouha B, Liu T et al. Proteolytic cleavage of livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspase. J Dermatol Sci 2006: 43: 189-200.
51. Nachmias B, Ashhab Y, Bucholtz V et al. Caspase-mediated cleavage converts livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res 2003: 63: 6340-6349.
52. Hussein M R, Haemel A K, Wood G S. Apoptosis and melanoma: Molecular mechanisms. J Pathol 2003: 199: 275-288.
53. Raisova M, Bektas M, Wieder T et al. Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release. FEBS Lett 2000: 473: 27-32.
54. Hakansson A, Gustafsson B, Abdiu A, Krysander L, Hakansson L. Bcl-2 expression in metastatic malignant melanoma. Importance for the therapeutic efficacy of biochemotherapy. Cancer Immunol Immunother 2003: 52: 249-254.
55. Hossini A M, Eberle J, Fecker L F, Orfanos C E, Geilen C C. Conditional expression of exogenous Bcl-X(S) triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts. FEBS Lett 2003: 553: 250-256.
56. Zhuang L, Lee C S, Scolyer R A et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007: 20: 416-426.
57. McGill G G, Horstmann M, Widlund H R et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002: 109: 707-718.
58. von Willebrand M, Kohler K, Alanko T, Laiho M, Saksela O. FGF-2 blocks TGF-beta 1-mediated suppression of Bcl-2 in normal melanocytes. Exp Dermatol 2005: 14: 202-208.
59. Oppermann M, Geilen C C, Fecker L F, Gillissen B, Daniel P T, Eberle J. Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk/Bik. Oncogene 2005: 24: 7369-7380.
60. Fecker L F, Geilen C C, Tchernev G et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 2006: 126: 1366-1371.
61. Raisova M, Hossini A M, Eberle J et al. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 2001: 117: 333-340.
62. Li-Weber M, Krammer P H. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 2003: 15: 145-157.
63. Eberle J, Fecker L F, Hossini A M et al. CD95/Fas signaling in human melanoma cells: Conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 2003: 22: 9131-9141.
64. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997: 388: 190-195.
65. Bullani R R, Huard B, Viard-Leveugle I et al. Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol 2001: 117: 360-364.
66. Zeise E, Weichenthal M, Schwarz T, Kulms D. Resistance of human melanoma cells against the death ligand TRAIL is reversed by ultraviolet-B radiation via downregulation of FLIP. J Invest Dermatol 2004: 123: 746-754.
67. Hamai A, Richon C, Meslin F et al. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. Oncogene 2006: 25: 7618-7634.
68. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005: 12: 228-237.
69. Franco A V, Zhang X D, Van Berkel E et al. The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 2001: 166: 5337-5345.
70. Ivanov V N, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003: 22: 3152-3161.
71. Kurbanov B M, Fecker L F, Geilen C C, Sterry W, Eberle J. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 2007: 26: 3364-3377.
72. Jansen B, Schlagbauer-Wadl H, Brown B D et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998: 4: 232-234.
73. Klasa R J, Gillum A M, Klem R E, Frankel S R. Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002: 12: 193-213.
74. Jansen B, Wacheck V, Heere-Ress E et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000: 356: 1728-1733.
75. Bedikian A Y, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006: 24: 4738-4745.
76. Bush J A, Li G. The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis 2003: 20: 531-539.
77. Zhang X D, Wu J J, Gillespie S, Borrow J, Hersey P. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clin Cancer Res 2006: 12: 1355-1364.
78. Thallinger C, Wolschek M F, Wacheck V et al. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 2003: 120: 1081-1086.
79. Heere-Ress E, Thallinger C, Lucas T et al. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer 2002: 99: 29-34.
80. Del B D, Trisciuoglio D, Scarsella M, Zangemeister-Wittke U, Zupi G. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 2003: 22: 8441-8447.
81. Hossini A M, Geilen C C, Fecker L F, Daniel P T, Eberle J. A novel Bcl-x splice product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain. Oncogene 2006: 25: 2160-2169.
82. Verhaegen M, Bauer J A, Martin V et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006: 66: 11348-11359.
83. Lickliter J D, Cox J, McCarron J et al. Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction. Br J Cancer 2007: 96: 600-608.
84. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 1996: 274: 1363-1366.
85. Chappell D B, Zaks T Z, Rosenberg S A, Restifo N P. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 1999: 59: 59-62.
86. Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993: 364: 806-809.
87. Fecker L F, Geilen C C, Hossini A M et al. Selective induction of apoptosis in melanoma cells by tyrosinase promoter-controlled CD95 ligand overexpression. J Invest Dermatol 2005: 124: 221-228.
88. Yagita H, Takeda K, Hayakawa Y, Smyth M J, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004: 95: 777-783.
89. LeBlanc H N, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003: 10: 66-75.
90. Walczak H, Miller R E, Ariail K et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999: 5: 157-163.
91. Shankar S, Chen X, Srivastava R K. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005: 62: 165-186.
92. Takeda K, Yamaguchi N, Akiba H et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004: 199: 437-448.
93. Kelley R F, Totpal K, Lindstrom S H et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005: 280: 2205-2212.
94. Hersey P, Zhang X D. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001: 1: 142-150.
95. Zhang X, Jin T G, Yang H, DeWolf W C, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004: 64: 7086-7091.
96. Kurbanov B M, Geilen C C, Fecker L F, Orfanos C E, Eberle J. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol 2005: 125: 1010-1019.
97. Singh T R, Shankar S, Chen X, Asim M, Srivastava R K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003: 63: 5390-5400.
98. Fulda S, Debatin K M. 5-Aza-2′-deoxycytidine IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 2006: 25: 5125-5133.
99. Alemany R, Balague C, Curiel D T. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000: 18: 723-727.
100. Vaha-Koskela M J, Heikkila J E, Hinkkanen A E. Oncolytic viruses in cancer therapy. Cancer Lett 2007: PMID: 17383089.
101. Russell W C. Update on adenovirus and its vectors. J Gen Virol 2000: 11: 2573-2604.
102. Bischoff J R, Kirn D H, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996: 274: 373-376.
103. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff D D, Kirn D H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997: 3: 639-645.
104. Doronin K, Kuppuswamy M, Toth K et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 2001: 75: 3314-3324.
105. Banerjee N S, Rivera A A, Wang M et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. Mol Cancer Ther 2004: 3: 437-449.
106. Raki M, Kanerva A, Ristimaki A et al. Combination of gemcitabine and Ad5/ 3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 2005: 12: 1198-1205.
107. Kuppuswamy M, Spencer J F, Doronin K, Tollefson A E, Wold W S, Toth K. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther 2005: 12: 1608-1617.
108. Cheng H, Snoek R, Ghaidi F, Cox M E, Rennie P S. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 2006: 66: 10613-10620.
109. Thorne S H, Tam B Y, Kirn D H, Contag C H, Kuo C J. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. Mol Ther 2006: 13: 938-946.
110. Ranki T, Sarkioja M, Hakkarainen T, Smitten K, Kanerva A, Hemminki A. Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. Int J Cancer 2007: 121: 2919-2928.
111. Hoffmann D, Wildner O. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment. Cancer Gene Ther 2007: 14: 627-639.
112. Hoffmann D, Wildner O. Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy. Mol Cancer Ther 2006: 5: 2013-2022.
113. Motoi F, Sunamura M, Ding L et al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther 2000: 11: 223-235.
114. Bernt K M, Ni S, Tieu A T, Lieber A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res 2005: 65: 4343-4352.
115. Toth K, Tarakanova V, Doronin K et al. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther 2003: 10: 193-200.
116. Sarkioja M, Kanerva A, Salo J et al. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. Cancer 2006: 107: 1578-1588.
117. Dix B R, O'Carroll S J, Myers C J, Edwards S J, Braithwaite A W. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res 2000: 60: 2666-2672.
118. Cherubini G, Petouchoff T, Grossi M, Piersanti S, Cundari E, Saggio I. E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells. Cell Cycle 2006: 5: 2244-2252.
119. Reid T, Galanis E, Abbruzzese J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res 2002: 62: 6070-6079.
120. Au T, Thorne S, Korn W M, Sze D, Kirn D, Reid T R. Minimal hepatic toxicity of Onyx-015: Spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther 2007: 14: 139-150.
121. Reid T R, Freeman S, Post L, McCormick F, Sze D Y. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 2005: 12: 673-681.
122. Nemunaitis J, Khuri F, Ganly I et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001: 19: 289-298.
123. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007: 7: 141-148.
124. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006: 98: 298-300.
125. Ferguson C A, Kidson S H. The regulation of tyrosinase gene transcription. Pigment Cell Res 1997: 10: 127-138.
126. Diaz R M, Eisen T, Hart I R, Vile R G. Exchange of viral promoter/ enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J Virol 1998: 72: 789-795.
127. Park B J, Brown C K, Hu Y et al. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum Gene Ther 1999: 10: 889-898.
128. Nettelbeck D M, Rivera A A, Balague C, Alemany R, Curiel D T. Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/ promoter. Cancer Res 2002: 62: 4663-4670.
129. Hurtado PicóA, Wang X, Sipo I et al. Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses. Mol Ther 2005: 11: 563-577.
130. Huang T G, Savontaus M J, Shinozaki K, Sauter B V, Woo S L. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 2003: 10: 1241-1247.
131. Kawashima T, Kagawa S, Kobayashi N et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004: 10: 285-292.
132. Wildner O, Morris J C. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. J Gene Med 2000: 2: 353-360.
133. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992: 89: 5547-5551.
134. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995: 268: 1766-1769.
135. Freundlieb S, Schirra-Muller C, Bujard H. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med 1999: 1: 4-12.
136. Urlinger S, Baron U, Thellmann M, Hasan M T, Bujard H, Hillen W. Exploring the sequence space for tetracycline-dependent transcriptional activators: Novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000: 97: 7963-7968.
137. Srour M A, Fechner H, Wang X et al. Regulation of human factor IX expression using doxycycline-inducible gene expression system. Thromb Haemost 2003: 90: 398-405.
138. Fechner H, Wang X, Srour M et al. A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication. Gene Ther 2003: 10: 1680-1690.
139. Sipo I, Wang X, Hurtado PicóA et al. Tamoxifen-regulated adenoviral E1A chimeras for the control of tumor selective oncolytic adenovirus replication in vitro and in vivo. Gene Ther 2006: 13: 173-186.
140. Sipo I, Hurtado PicóA, Wang X et al. An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy. J Mol Med 2006: 84: 215-225.
141. Fechner H, Wang X, Pico A H et al. A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication. J Biotechnol 2007: 127: 560-574.